Difference between revisions of "Fluorouracil (5-FU)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 10: Line 10:
 
*[[Bladder cancer]]
 
*[[Bladder cancer]]
 
*[[Breast cancer]]
 
*[[Breast cancer]]
 +
*[[Carcinoma of unknown primary]]
 
*[[Cervical cancer]]
 
*[[Cervical cancer]]
 
*[[Cholangiocarcinoma]]
 
*[[Cholangiocarcinoma]]
Line 23: Line 24:
 
*[[Prostate cancer]]
 
*[[Prostate cancer]]
 
*[[Rectal cancer]]
 
*[[Rectal cancer]]
−
*[[SCC of unknown primary]]
 
  
 
==Diseases for which it was used==
 
==Diseases for which it was used==
Line 139: Line 139:
 
[[Category:Bladder cancer medications]]
 
[[Category:Bladder cancer medications]]
 
[[Category:Breast cancer medications]]
 
[[Category:Breast cancer medications]]
 +
[[Category:Carcinoma of unknown primary medications]]
 
[[Category:Cervical cancer medications]]
 
[[Category:Cervical cancer medications]]
 
[[Category:Cholangiocarcinoma medications]]
 
[[Category:Cholangiocarcinoma medications]]
Line 152: Line 153:
 
[[Category:Prostate cancer medications]]
 
[[Category:Prostate cancer medications]]
 
[[Category:Rectal cancer medications]]
 
[[Category:Rectal cancer medications]]
−
[[Category:SCC of unknown primary medications]]
 
  
 
[[Category:FDA approved in 1962]]
 
[[Category:FDA approved in 1962]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Revision as of 14:27, 26 June 2021

General information

Class/mechanism: Pyrimidine analog, antimetabolite, inhibitor of thymidylate synthase. Metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP).[1][2].
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 4/25/1962: Initial FDA approval

Also known as

  • Code name: Ro-2-9757
  • Generic names: 5 Fluorouracil, 5 FU, 5-fluoracilo, 5-fluorouracilo, 5-fluorouracyl, FU
  • Brand names:
Synonyms
Accusite Actino Hermal Adrucil Arumel Benton Biofur Carac Carebin
Carzonal Cinco-FU Cinkef-U Curacil Effcil Efudex Efurix Ezadex
Fauldfluor Fivocil Fivoflu Flacule Flonida Florac Fluhomer Fluolex
Fluoroplex Fluor-Uracil Fluoro-Uracile ICN Fluoro-Uracil ICN Fluorouracile Fluorouracilo Fluorourcil Fluoruracilo
Fluoxan Flurablastin Flurac Fluracedyl Fluracil Fluril Fluroblastin Fluroblastine
Ftoruracil Ftouracil Haemato-FU Ifacil Kang Ning Kecimeton Tatumi Killit Lunachol
Lunapon Natira U Neofluor O Fluor Oncofu Onkofluor Pentafu Pharmauracil
Phthoruracil Phtoruracil Ribofluor Rotianin Satelol Seco Uracil Tecflu Timadin
Triosules Uflahex Ulosagen Ulup Uraciflor Utoral Vaflu Vafu

References

  1. ↑ 1.0 1.1 Fluorouracil (5-FU) package insert (locally hosted backup)
  2. ↑ 5-FU pathway
  3. ↑ Fluorouracil (5-FU) Package Insert
  4. ↑ Fluorouracil (5-FU) patient drug information (Chemocare)
  5. ↑ Fluorouracil (5-FU) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Fluorouracil_(5-FU)&oldid=50860"